A detailed history of Snowden Capital Advisors LLC transactions in Incyte Corp stock. As of the latest transaction made, Snowden Capital Advisors LLC holds 3,946 shares of INCY stock, worth $271,642. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,946
Holding current value
$271,642
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $226,224 - $270,735
3,946 New
3,946 $260,000
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $12,741 - $15,384
-193 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $12,224 - $14,303
193 New
193 $14,000
Q1 2020

Jan 08, 2024

SELL
$63.18 - $85.97 $6.55 Million - $8.91 Million
-103,600 Closed
0 $0
Q4 2019

Jan 08, 2024

BUY
$73.04 - $95.72 $29,216 - $38,288
400 Added 0.39%
103,600 $90.5 Million
Q3 2019

Jan 08, 2024

BUY
$72.82 - $86.52 $2.05 Million - $2.44 Million
28,200 Added 37.6%
103,200 $76.6 Million
Q2 2019

Jan 08, 2024

BUY
$73.52 - $88.7 $5.51 Million - $6.65 Million
75,000 New
75,000 $88.5 Million
Q2 2018

Jan 08, 2024

SELL
$60.85 - $83.98 $1.38 Million - $1.9 Million
-22,649 Closed
0 $0
Q1 2018

Jan 08, 2024

BUY
$83.06 - $100.98 $6,727 - $8,179
81 Added 0.36%
22,649 $1.89 Billion
Q4 2017

Jan 08, 2024

SELL
$93.56 - $116.6 $205,083 - $255,587
-2,192 Reduced 8.85%
22,568 $2.14 Billion
Q3 2017

Jan 08, 2024

BUY
$109.15 - $138.27 $27,069 - $34,290
248 Added 1.01%
24,760 $2.89 Billion
Q2 2017

Jan 08, 2024

BUY
N/A
2,803 Added 12.91%
24,512 $3.09 Billion
Q1 2017

Jan 08, 2024

BUY
N/A
557 Added 2.63%
21,709 $2.9 Billion
Q4 2016

Jan 08, 2024

BUY
N/A
8,925 Added 72.99%
21,152 $2.12 Billion
Q3 2016

Jan 08, 2024

BUY
N/A
12,227
12,227 $1.15 Billion

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Snowden Capital Advisors LLC Portfolio

Follow Snowden Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Snowden Capital Advisors LLC with notifications on news.